| Literature DB >> 34463776 |
Nebiyat F Belachew1, Eike I Piechowiak2, Tomas Dobrocky2, Thomas R Meinel3, Arsany Hakim2, Enrique A Barvulsky2, Jan Vynckier3, Marcel Arnold3, David J Seiffge3, Roland Wiest2, Urs Fischer3, Jan Gralla2, Johannes Kaesmacher2,4, Pasquale Mordasini2.
Abstract
BACKGROUND ANDEntities:
Keywords: Clot characteristics; MRI; Reperfusion; Stent retriever; Thrombectomy
Mesh:
Substances:
Year: 2021 PMID: 34463776 PMCID: PMC9187552 DOI: 10.1007/s00062-021-01079-1
Source DB: PubMed Journal: Clin Neuroradiol ISSN: 1869-1439 Impact factor: 3.156
Fig. 1A patient with acute ischemic stroke and complete occlusion of the left middle cerebral artery (MCA) main trunk (M1 segment). SVS visible on SWI (a) as signal loss along the main trunk of the MCA representing the occlusive thrombus. Vessel occlusion is also seen on arterial time-of-flight sequence (aTOF; b) and on digital subtraction angiography (c). Yellow crosshairs are centered on the proximal end of the vessel occlusion on SWI (a) and on aTOF (b). The blue arrow points to the proximal end of the vessel occlusion on digital subtraction angiography (c)
Fig. 2A patient with acute ischemic stroke. Susceptibility-weighted imaging (SWI) shows no SVS (a). Complete proximal occlusion of the left middle cerebral artery (MCA) main trunk (M1-segment) is seen on arterial time-of-flight sequence (aTOF; b) and on digital subtraction angiography (c). Yellow crosshairs are centered on the proximal end of the vessel occlusion on SWI (a) and aTOF (b). The blue arrow points to the proximal end of the vessel occlusion on digital subtraction angiography (c)
List of stent retriever devices used in this study
| Device name | Size (mm)a | Number of patients treated |
|---|---|---|
| Solitaire FR (Medtronic, Irvine, California, USA)b | 4 × 20/6 × 30/4 × 40 | 425 |
| Catch (Balt, Montmorency, France)b | 3 × 15/4 × 20/5 × 35 | 35 |
| Mindframe (Medtronic, Irvine, California, USA)c | 3 × 15 | 21 |
| Trevo Provue (Stryker, Kalamazoo, Michigan, USA)c | 4 × 30/6 × 25 | 10 |
| Embotrap (Nauravi, Galway, Ireland)c | 5 × 21 | 5 |
| Preset LT (Phenox, Bochum, Germany)b | 4 × 20 | 1 |
aFor each device, the first value is the nominal diameter and the second value is the usable stent length expressed in mm
bIncomplete axial section device
cComplete axial section device
Baseline characteristics and clinical data upon admission for the stent retriever (SR) and combined approach (COA) group
| Data available for ( | All patients | SR ± BGC | COA ± BGC | P‑value | |
|---|---|---|---|---|---|
| Age | 497/497 (100%) | 74.7 (62.6–82.0) | 74.5 (62.5–82.3) | 75.0 (62.5–81.5) | 0.943 |
| Sex, female | 497/497 (100%) | 51.7% (257) | 52.6% (154) | 50.5 (103) | 0.650 |
| Hypertension | 497/497 (100%) | 66.6% (331) | 66.2% (194) | 32.8% (67) | 0.826 |
| Smoking | 497/497 (99.8%) | 26.4% (131) | 28.3% (83) | 23.5% (48) | 0.224 |
| Diabetes mellitus | 497/497 (100%) | 14.1% (70) | 15.4% (45) | 12.3% (25) | 0.328 |
| Coronary heart disease | 493/497 (99.2%) | 15.3% (76) | 15.4% (45) | 15.2% (31) | 0.972 |
| Dyslipidemia | 495/497 (99.6%) | 58.4% (290) | 58.7% (172) | 57.8% (118) | 0.863 |
| Previous stroke | 497/497 (100%) | 11.3% (56) | 11.6% (34) | 10.8% (22) | 0.776 |
| Pre-stroke mRS > 2 | 496/497 (99.8%) | 8.2% (41) | 7.8% (23) | 8.8% (18) | 0.706 |
| None | – | 67.4% (335) | 69.3% (203) | 64.7% (132) | – |
| Mono | – | 30.2% (150) | 28.7% (84) | 32.4% (66) | – |
| Dual | – | 2.0% (10) | 1.7% (5) | 2.5% (5) | – |
| None | – | 87.1% (433) | 86.7% (254) | 87.7% (179) | – |
| Vitamin K antagonist | – | 6.2% (31) | 6.5% (19) | 5.9% (12) | – |
| NOAC | – | 6.0% (30) | 6.1% (18) | 5.9% (12) | – |
| Statin | – | 25.4% (126) | 26.6% (78) | 23.5% (48) | 0.441 |
| Systolic BP, mmHg | 487/497 (98.0%) | 155.0 (135.0–173.0) | 152.0 (134.0–171.8) | 158.0 (137.0–175.0) | 0.121 |
| Diastolic BP, mmHg | 488/497 (98.2%) | 81.0 (71.0–95.0) | 80 (70.5–95.0) | 83.0 (72.0–94.0) | 0.800 |
| Admission glucose, mmol/L | 488/497 (98.2%) | 6.5 (5.8–7.5) | 6.5 (5.7–7.7) | 6.4 (5.8–7.1) | 0.088 |
| Admission NIHSS | 497/497 (100%) | 12 (7–18) | 13 (8–18) | 11 (6–17) | 0.002a |
Data are expressed as percentage (n) or median (interquartile range 25–75%)
BP blood pressure, DWI-ASPECTS diffusion-weighted imaging Alberta stroke program early CT score, NIHSS National Institutes of Health Stroke Score, NOAC new oral anticoagulants, mRS modified Rankin scale, BP blood pressure
aStatistically significant
Stroke-related clinical and imaging data for the stent retriever (SR) and combined approach (COA) group
| Data available for ( | All patients | SR ± BGC | COA ± BGC | P‑value | |
|---|---|---|---|---|---|
| – | – | – | |||
| Large-artery atherosclerosis | – | 10.7% (53) | 10.6% (31) | 10.8% (22) | – |
| Cardioembolic | – | 46.9% (233) | 47.1% (138) | 46.6% (95) | – |
| Other determined causes | – | 5.0% (25) | 6.1% (18) | 3.4% (7) | – |
| Undetermined | – | 37.0% (184) | 35.8% (105) | 38.7% (79) | – |
| 1.5 T | – | 65.4% (325) | 65.9% (193) | 46.6% (95) | – |
| 3 T | – | 34.6% (172) | 34.1 (100) | 3.4% (7) | – |
| Time SO/LSW to admission (min) | 486/497 (97.8%) | 122.5 (71.0–286.0) | 114.0 (69.0–268.0) | 133.0 (73.0–310.0) | 0.104 |
| IV lysis prior to MRI | 497/497 (100%) | 6.4% (32) | 5.8% (17) | 7.4% (15) | 0.488 |
| IV lysis prior to MT | 497/497 (100%) | 38.8% (193) | 37.9% (111) | 40.2% (82) | 0.603 |
| Time SO/LSW to groin puncture (min) | 490/497 (98.6%) | 231.0 (164.8–386.5) | 229.0 (164.0–372.3) | 240.0 (165.8–452.0) | 0.317 |
| Time to reperfusion (min) | 471/497 (94.8%) | 41.0 (28.0–63.0) | 36.0 (25.0–60.0) | 47.0 (31.8–71.3) | 0.000a |
| Intracranial ICA | – | 13.9% (69) | 16.0% (47) | 10.8% (22) | – |
| MCA (M1) | – | 59.8% (297) | 68.9% (202) | 46.6% (95) | – |
| MCA (M2) | – | 23.7% (118) | 13.7% (40) | 38.2% (78) | – |
| MCA (M3) | – | 0.6% (3) | 0.0% (0) | 1.5% (3) | – |
| MCA and ACA involved | – | 1.0% (5) | 1.0% (3) | 1.0% (2) | – |
| ACA | – | 1.0% (5) | 0.3% (1) | 2.0% (4) | – |
| Tandem occlusion | – | 84.1% (418) | 8.2% (24) | 27.0% (55) | 0.000a |
| DWI-ASPECTS | 493/497 (99.2%) | 8 (6–9) | 8 (5–9) | 8 (7–9) | 0.020 |
| SVS | 497/497 (100%) | 87.9% (437) | 88.1% (258) | 87.7% (179) | 0.917 |
Data are expressed as percentage (n) or median (interquartile range 25–75%)
ACA anterior cerebral artery, DWI-ASPECTS diffusion-weighted imaging Alberta stroke program early CT score, ICA internal carotid artery, IV intravenous, LSW last seen well, MCA middle cerebral artery, SO symptom onset, SVS susceptibility vessel sign, T Tesla, TOAST trial of Org 10,172 in acute stroke treatment,
aStatistically significant
Interventional and clinical outcome results for the stent retriever (SR) and combined approach (COA) group
| Data available for ( | All patients | SR ± BGC | COA ± BGC | P‑value | |
|---|---|---|---|---|---|
| ≤ 3 | – | 90.3% (449) | 90.8% (266) | 89.7% (183) | – |
| 4–5 | – | 8.7% (43) | 8.5% (25) | 8.8% (28) | – |
| ≥ 6 | – | 1.0 (5) | 0.7% (2) | 1.5% (3) | – |
| Final eTICI ≥ 2b | 497/497 (100%) | 82.9% (412) | 82.3% (241) | 83.8% (171) | 0.647 |
| First-pass eTICI ≥ 2b | 466/497 (93.8%) | 55.3% (275) | 54.6% (160) | 56.4% (115) | 0.765 |
| NIHSS 24 h | 437/497 (87.9%) | 5 (2–12) | 5 (2–12) | 6 (2–12) | 0.837 |
| NIHSS imp. 24 h (total) | 437/497 (87.9%) | −4 (−9 to 0) | −5 (−10 to −1) | −2 (−7 to 0) | 0.001a |
| NIHSS imp. 24h ≥ 4 points | 437/479 (87.9%) | 44.7% (222) | 51.5% (151) | 34.8% (71) | 0.001a |
| mRS after 90 days | 478/497 (98.0%) | 2 (1–4) | 1 (1–2) | 1 (1–2) | 0.596 |
| Post-stroke mRS ≤ 2 | 478/497 (98.0%) | 52.9% (263) | 54.9% (161) | 50.0% (102) | 0.322 |
| Mortality within 90 days | 478/497 (98.0%) | 18.7% (93) | 19.1% (56) | 18.1% (37) | 0.825 |
| Peri-interventional complications | 496/497 (99.8) | 14.5% (72) | 14.3% (42) | 14.7% (30) | 0.920 |
| Embolization into new territory | 496/497 (99.8) | 3.8% (19) | 3.8% (11) | 3.9% (8) | 0.930 |
| Symptomatic intracerebral hemorrhage | 495/497 (99.6%) | 4.2% (21) | 3.8% (11) | 4.9% (10) | 0.529 |
Data are expressed as percentage (n) or median (interquartile range 25–75%)
eTICI expanded thrombolysis in cerebral infarction, mRS modified Rankin scale, NIHSS National Institutes of Health Stroke Score
aStatistically significant
Fig. 3First-pass expanded treatment in cerebral infarction (eTICI) distribution according to SR-based retrieval technique for patients with acute anterior circulation stroke with susceptibility vessel sign
Fig. 4First-pass expanded treatment in cerebral infarction (eTICI) distribution according to first-line SR-based retrieval technique for patients with acute anterior circulation stroke without susceptibility vessel sign